Article

LKB1 loss rewires JNK-induced apoptotic protein dynamics through NUAKs and sensitizes KRAS-mutant NSCLC to combined KRASG12C + MCL-1 blockade

2022-12-06

Abstract excerpt

<title>Abstract</title> The efficacy of molecularly targeted anti-cancer therapies may be limited by the presence of co-occurring mutations within a tumor.1-3 Conversely, these alterations may confer collateral vulnerabilities that can be leveraged for the development of novel therapeutic approaches. <italic>KRAS </italic>mutant lung cancers are distinguished by recurrent mutations in tumor suppress...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 3cf6cea7-1207-5205-8c6f-c2d48ca6909c
DOI: 10.21203/rs.3.rs-2334763/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

LKB1 loss rewires JNK-induced apoptotic protein dynamics through NUAKs and sensitizes KRAS-mutant NSCLC to combined KRASG12C + MCL-1 blockadeDOI 10.21203/rs.3.rs-2334763/v1Read

Molecular insights and therapeutic implications for the tumor suppressor role of LKB1 in non-small cell lung cancer.Semantic proximity Read

STK11/LKB1 Modulation of the Immune Response in Lung Cancer: From Biology to Therapeutic Impact.Semantic proximity Read

KEAP1 and STK11/LKB1 alterations enhance vulnerability to ATR inhibition in KRAS mutant non-small cell lung cancerSemantic proximity Read

LKB1 Loss induces characteristic patterns of gene expression in human tumors associated with NRF2 activation and attenuation of PI3K-AKT.Semantic proximity Read

Oncogenic KRAS mutation confers chemoresistance by upregulating SIRT1 in non-small cell lung cancerSemantic proximity Read

A transcriptional signature of LKB1 functional loss defines a large, therapeutically addressable patient population across human cancersSemantic proximity Read

An integrative approach unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and pancreatic cancer.Semantic proximity Read

Inhibition of ULK1/2 and KRAS G12C controls tumor growth in preclinical models of lung cancerSemantic proximity Read

Insights into targeting LKB1 in tumorigenesisSemantic proximity Read

STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.Semantic proximity Read

LKB1/KRAS mutant lung cancers constitute a genetic subset of NSCLC with increased sensitivity to MAPK and mTOR signalling inhibition.Semantic proximity Read

Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1.Semantic proximity Read